GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (NAS:KPRX) » Definitions » Cyclically Adjusted PB Ratio

Kiora Pharmaceuticals (Kiora Pharmaceuticals) Cyclically Adjusted PB Ratio : (As of May. 01, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Kiora Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kiora Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiora Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Kiora Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kiora Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Kiora Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Kiora Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Kiora Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.793/129.4194*129.4194
=0.793

Current CPI (Dec. 2023) = 129.4194.

Kiora Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 -5,071.667 99.695 -6,583.835
201406 -4,049.611 100.560 -5,211.822
201409 -4,001.901 100.428 -5,157.174
201412 -4,045.549 99.070 -5,284.891
201503 201.511 99.621 261.786
201506 84.630 100.684 108.784
201509 680.016 100.392 876.641
201512 477.038 99.792 618.664
201603 479.295 100.470 617.396
201606 433.512 101.688 551.735
201609 203.066 101.861 258.005
201612 -19.491 101.863 -24.764
201703 -63.210 102.862 -79.530
201706 159.365 103.349 199.566
201709 23.683 104.136 29.433
201712 -67.003 104.011 -83.371
201803 183.519 105.290 225.577
201806 191.789 106.317 233.465
201809 153.294 106.507 186.272
201812 122.428 105.998 149.480
201903 132.162 107.251 159.480
201906 111.283 108.070 133.268
201909 68.660 108.329 82.027
201912 64.960 108.420 77.542
202003 80.557 108.902 95.735
202006 67.416 108.767 80.217
202009 51.535 109.815 60.735
202012 70.045 109.897 82.488
202103 71.485 111.754 82.785
202106 58.912 114.631 66.512
202109 54.989 115.734 61.491
202112 46.049 117.630 50.664
202203 35.559 121.301 37.939
202206 26.821 125.017 27.766
202209 9.750 125.227 10.076
202212 6.350 125.222 6.563
202303 5.292 127.348 5.378
202306 1.974 128.729 1.985
202309 1.054 129.860 1.050
202312 0.793 129.419 0.793

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kiora Pharmaceuticals  (NAS:KPRX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Kiora Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Kiora Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiora Pharmaceuticals (Kiora Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
332 Encinitas Blvd, Suite 102, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. It operates in one reportable segment operations and manages.
Executives
Carmine N. Stengone director 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Melissa Tosca officer: EVP of Finance C/O KIORA PHARMACEUTICALS, INC., 1371 EAST 2100 SOUTH, SUITE 200, SALT LAKE CITY UT 84105
Susan L. Drexler officer: Interim CFO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Erin Parsons director 97 WILLISTON RD, BROOKLINE MA 02445
David Hollander director C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Brian M. Strem director, officer: President and CEO C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Eric Joseph Daniels officer: Chief Development Officer C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Armistice Capital Master Fund Ltd. director, 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Aron Shapiro director C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Kenneth L Gayron director 75 NETWORK DRIVE, BURLINGTON MA 34212
Franz Obermayr officer: Acting CEO C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108, WALTHAM MA 02452
Bernard Malfroy-camine director C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110
Thomas Hancock director C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110